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Abstract
Over the last decade, important clinical benefits have been achieved in cancer patients by using drug-targeting strategies. 
Nevertheless, drug resistance is still a major problem in most cancer therapies. Epithelial-mesenchymal plasticity (EMP) and 
tumour microenvironment have been described as limiting factors for effective treatment in many cancer types. Moreover, 
epithelial-to-mesenchymal transition (EMT) has also been associated with therapy resistance in many different preclinical 
models, although limited evidence has been obtained from clinical studies and clinical samples. In this review, we particularly 
deepen into the mechanisms of which intermediate epithelial/mesenchymal (E/M) states and its interconnection to microen-
vironment influence therapy resistance. We also describe how the use of bioinformatics and pharmacogenomics will help to 
figure out the biological impact of the EMT on drug resistance and to develop novel pharmacological approaches in the future.
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Abbreviations
ECM  Extracellular matrix
CAFs  Cancer-associated fibroblast
EMT  Epithelial-to-mesenchymal transition
E/M  Epithelial/mesenchymal states
HIF  Hipoxia-iducible factors
MDR  Multidrug resistance
NSCLC  Non-small cell lung cancer
SCLC  Small cell lung cancer
TAMs  Tumour associated macrofges
TFs  Transcription factors
TME  Tumour microenvironment
Background
At present, one of the most important challenges in oncol-
ogy is to overcome therapy resistance, as it is a persis-
tent problem for cancer patient management. Frequently, 
patients with resistance also develop more metastases, and 
given that metastasis is the major cause of cancer-related 
deaths in human carcinomas, it is important to overcome 
therapy resistance by using new targeted-therapy strategies. 
Therapy resistance not only includes the traditionally well-
established innate and acquired tumour drug resistance, 
but it also includes resistance to treatment such as chemo 
or radiotherapy, immune- and targeted-therapies (Burrell 
and Swanton 2016; Assaraf et al. 2019; Vasan et al. 2019). 
Important molecular mechanisms involved in drug resist-
ance have been well determined by the effect of a decreased 
drug uptake by altered influx transporters, an increased drug 
efflux by the overexpression of multidrug-resistance (MDR) 
efflux transporters or an altered expression of anti-apoptotic 
proteins (Assaraf et al. 2019). However, still limited under-
standing of the molecular mechanisms involved in therapy 
resistance has been elucidated. Epithelial-to-mesenchymal 
transition (EMT) has emerged as a major contributor to ther-
apy resistance. EMT is a highly conserved cellular program 
that allows polarized, immobile epithelial cells to transform 
into mesenchymal, mobile cells because of the loss of apico-
basal polarity, the loss of cell–cell contacts, the reorganiza-
tion of the actin cytoskeleton, and the ability to invade the 
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extracellular matrix as an individual cell. EMT is related to 
tumour progression, metastasis and mediates resistance to 
conventional therapies and small-molecule targeted inhib-
itors (Thiery et al. 2009; Chaffer et al. 2016; Yang et al. 
2020). Important studies using tumour cell lines demonstrate 
the implication of EMT in resistance driven by radio- or 
chemotherapy (Inoue et al. 2002; Olmeda et al. 2007). How-
ever, insufficient in vivo information is available mainly due 
to the absence of suitable in vivo models and limited human 
samples analyzed to perform comprehensive studies. On the 
other hand, it is important to highlight that intermediate epi-
thelial and mesenchymal (E/M) phenotypic states coexists 
in a carcinoma, therefore different subpopulation are found, 
increasing the level of plasticity within the tumour (Yang 
et al. 2020). Although the influence of these intermediate 
E/M states on resistance to anticancer therapeutics drugs is 
not fully understood, pharmacogenomics approaches impact 
on this relevant aspect. Moreover, an important link between 
EMT and tumour microenvironment has arisen as a state of 
the art of research in oncology, highlighting the need of per-
sonalized treatments for individual cancer patients (Shibue 
and Weinberg 2017; Maman and Witz 2018; Gupta et al. 
2019; Recasens and Munoz 2019; Boumahdi and de Sau-
vage 2020). Given the recent outstanding contributions pub-
lished on the importance of tumour microenvironment and 
EMT in multidrug resistance (MDR), this issue will be not 
further discussed (Erin et al. 2020). In this review, we will 
go in depth into the molecular mechanism by which EMT 
induce therapy resistance and how the microenvironment 
contribute to this process. Moreover, future perspectives on 
bioinformatic and pharmacological approaches to overcome 
therapies resistance will be also discussed.
Epithelial‑to‑mesenchymal transition 
and tumour resistance: evidences in vitro, 
in vivo and in clinical studies
The cancer EMT program is a cellular and molecular process 
by which epithelial tumour cells lose cell–cell contacts and 
apico–basal polarity, acquiring mesenchymal characteris-
tics (Brabletz et al. 2018; Yang et al. 2020). Importantly, 
EMT is a highly dynamic and reversible process, on which 
mesenchymal cells can revert to epithelial phenotype by 
mesenchymal-to-epithelial transition process (MET) (Thiery 
et al. 2009). Intermediate cellular states, E/M hybrid phe-
notypes, coexist within the tumour harboring high degree 
of epithelial–mesenchymal plasticity (EMP). The epithelial-
to-mesenchymal plasticity is tightly regulated at a transcrip-
tional, post-transcriptional and post-translational level, with 
important clinical implications (Sabbah et al. 2008; Aparicio 
et al. 2013, 2015). The loss of expression of E-cadherin pro-
tein at cell–cell contacts is a hallmark of the EMT, which 
is accompanied by the downregulation of other epithelial 
proteins, such as cytokeratins, claudins, and the upregulation 
of mesenchymal markers, such as N-cadherin, Vimentin or 
Fibronectin (Nieto et al. 2016; Brabletz et al. 2018; Yang 
et al. 2020). Moreover, several transcription factors (TFs) 
are involved in the EMT, as the repressors of E-cadherin pro-
moter including the Snail/Slug family, Twist, Zeb1 and Zeb2 
(Batlle et al. 2000; Cano et al. 2000). The loss of E-cadherin 
is also regulated by posttranscriptional regulators (such as 
miR-200 family or RNA-binding proteins) or by posttrans-
lational regulators (such as CK1 or Hakai) (Park et al. 2008; 
Gregory et al. 2008; Sarkar et al. 2010; Wang et al. 2010; 
Aparicio et al. 2013).
Although many publications have reported the implica-
tion of EMT on cancer metastasis, important articles support 
that EMT program is dispensable in this process (Arumugam 
et al. 2009; Fischer et al. 2015; Zheng et al. 2015). How-
ever, the relationship between EMT and therapy resistance 
is increasingly established. Indeed, the link between EMT 
and cancer stemness and their influence on drug resistance 
has been recently reported, therefore this topic will be not 
recapitulated in detail (Koren and Fuchs 2016; Chaffer et al. 
2016; Shibue and Weinberg 2017; Dongre and Weinberg 
2019). The general mechanism regarding EMT-associated 
drug resistance is related to increased drug efflux, slow cell 
proliferation and avoiding apoptosis signaling pathways. 
Moreover, avoiding immune response is another impor-
tant mechanism by which EMT contributes to therapeutic 
resistance, by altering expression of molecules involved in 
immunosuppression or immunoevasion (Shibue and Wein-
berg 2017; Gupta et al. 2019; Dongre and Weinberg 2019). 
Although EMT can have an impact on drug resistance in sev-
eral preclinical models (Shibue and Weinberg 2017; Gupta 
et al. 2019), the understanding of the molecular mechanism 
is poorly understood as recapitulated below. Many publica-
tions highlight the impact of EMT in vitro, in vivo and in 
clinical specimens. It is reported the implication of tran-
scriptional or posttranslational EMT-related regulators in 
resistance to anticancer therapeutic drugs (Kajita et al. 2004; 
Yauch et al. 2005; Olmeda et al. 2007; Saxena et al. 2011; 
Shibue and Weinberg 2017; Weng et al. 2019; Dongre and 
Weinberg 2019; Boumahdi and de Sauvage 2020). Here, we 
will discuss recent EMT studies in different cancer models.
Perhaps the most controversial studies in this field were 
reported in vivo, using transgenic mice models (Fischer et al. 
2015; Zheng et al. 2015). Using a EMT lineage tracing a 
triple transgenic mice of breast cancer, it was demonstrated 
that inhibition of EMT by overexpression of miR-200a 
and, in consequence, the abolition of the EMT-TFs Zeb1 
and Zeb2, abrogated chemoresistance to cyclophospha-
mide (Fischer et al. 2015). Additionally, by deleting Snail 
or Twist TFs in genetically engineered mouse models of 
pancreatic ductal adenocarcinoma resulted in an enhanced 
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expression of nucleoside transporters in tumours, which 
in turn increased the sensitivity to gemcitabine treatment 
(Zheng et al. 2015). Although both studies were very con-
troversial as the contribution of EMT on cancer metastasis 
was not supported, this affirmation was later argued (Aiello 
et al. 2017; Ye et al. 2017). However, the involvement of 
the EMT in drug resistance was very well demonstrated in 
these two in vivo preclinical models, and the implication of 
EMT in chemoresistance underscored the potential benefit 
of combining EMT inhibition with chemotherapy for the 
cancer treatment.
Apart from these two important contributions using trans-
genic mice models, the majority of data linking EMT to 
chemoresistance is supported by in vitro studies, xenograft 
tumours using athymic mice, and in clinical specimens. Per-
haps, lung cancer is one the best type of cancer on which 
the link between EMT and resistance to therapy is well 
documented. It has been demonstrated that targeting FGFR 
prevents the development of EMT-mediated resistance in 
EGFR mutant NSCLC (Raoof et al. 2019). On the other 
hand, epigenetic silencing of miR-483-3p has been reported 
to promote acquired gefitinib resistance and EMT in EGFR-
mutant NSCLC (Yue et al. 2018). Many publications under-
score the implication of EMT-TFs in drug resistance (Fig. 1). 
For instance, the overexpression of Snail and Slug has been 
reported to induce gefitinib resistance in EGFR-mutant lung 
cancer cell lines (Lee et al. 2017a). Moreover, PAX6 has 
been demonstrated to induce EMT and cisplatin resistance 
through the regulation of Zeb2 expression (Wu et al. 2019a). 
The upregulation of the EMT-associated gene AXL, has 
been described to predict acquired resistance to EGFR-TKI 
osimertinib (Namba et al. 2019). The molecular mechanism 
proposed for this therapy resistance is the participation of 
cell stem characteristics, the repression of the proapoptotic 
protein Bcl-2-like protein 11 or the chromatin remodeling 
driven by EMT-TFs (Sayan et al. 2009; Song et al. 2018). 
Moreover, MET-driven EMT has also been demonstrated to 
induce chemoresistance. On the one hand, cisplatin-resistant 
NSCLC cell lines showed MET overexpression compared 
to parental ones, which is accompanied by and increased 
expression of N-cadherin, Vimentin, Zeb1 and Snail, and 
a decreased expression of E-cadherin. On the other hand, 
mir-206-mediated MET downregulation not only reversed 
EMT but also sensitized resistant NSCLC cells to cisplatin 
(Chen et al. 2016).
In breast cancer, it was described that the overexpres-
sion TFs such as Twist, Snail, and FOXC2 increases the 
promoter activity of ABC transporters, indicating that EMT 
inducers are novel regulators of ABC transporters. Therefore 
EMT-TFs are proposed as novel strategies to treat metasta-
sis and the associated drug resistance (Saxena et al. 2011). 
Importantly, it has been elucidated that intermediate E/M 
phenotypes in breast cancer cells are more effective in devel-
oping drug resistance and metastasis than when a complete 
mesenchymal state has occurred (Jolly et al. 2019). One of 
the molecular mechanisms proposed for this resistance in 
mesenchymal-like triple-negative breast cancer cells is due 
to the expression of ITGB4 + in intermediate states, regu-
lated by Zeb1 through its repression on Tap63α expression, a 
protein that promotes ITGB4 expression (Bierie et al. 2017). 
Another important example of the implication of EMT-TFs 
in drug resistance was reported in normal and transformed 
Fig. 1  Targeting cancer epithelial tumour plasticity to overcome 
resistance. Tumour cells with epithelial phenotype can undergo 
epithelial-to-mesenchymal transition program at primary tumour 
site. Epithelial cells loose cell–cell contacts and aquiere invasive 
and migratory capabilities. The existence of intermediate epithe-
lial/mesenchymal marker proteins in cancer cells with partial E/M 
hybrid phenotype is associated with increased cellular plasticity and 
stemness. Several transcription factors, post-trasncriptional and post-
translational regulators of the EMT are implicated in therapy resist-
ance
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human mammary epithelial on which induction of Twist 
overexpression or E-cadherin inhibition confer resistance to 
paclitaxel and doxorubicin. On the other hand, Snail confers 
resistance to docetaxel and gemcitabine in basal-like breast 
cancer MDA-MB-231 cells. However, breast cancer cells 
with mesenchymal characteristics are sensitive to paclitaxel. 
Indeed, it has been demonstrated that induction of EMT acti-
vates PERK-eIF2α and sensitizes cells to agents that perturb 
endoplasmic reticulum function, which shows a new vulner-
ability of cancer cells that undergo EMT, consisting in the 
sensitivity to endoplasmic reticulum stress (Olmeda et al. 
2007; Gupta et al. 2009; Feng et al. 2014). Importantly, by 
using in vitro and in xenograft models, the link between 
EMT and endocrine therapy resistance in luminal breast can-
cer has been reported. Indeed, when estrogen receptor alpha 
gene (ESR1) fusion proteins is expressed in breast cancer 
cell lines it promotes an estrogen-independent activation of 
EMT by Snail upregulation and E-cadherin downregulation 
(Lei et al. 2018). Other examples of the link between EMT 
and therapy resistance have been shown in prostate and ovar-
ian cancer. Indeed, prostate tumour resistance to cabazitaxel 
can be overcome by antiandrogen-mediated EMT-MET in 
androgen-sensitive tumours but not in metastatic castration-
resistant prostate cancer patients, who frequently develop 
therapeutic resistance to taxane chemotherapy and antian-
drogens. On the other hand, Lysyl oxidase-like 2 (LOXL2), a 
protein that induces EMT, is involved in radiotherapy resist-
ance in prostate cancer cells and in xenografts mice model 
(Cano et al. 2012; Martin et al. 2016). In ovarian cancer, the 
EMT-TFs Snail and Slug drive chemo and radioresistance 
through the p53-driven apoptosis and regulation of stem 
properties (Kurrey et al. 2009). In colorectal cancer, miR-
128-3p reverses oxaliplatin resistance in colorectal cancer 
through the downregulation of Bmi1 and MRP5, two genes 
involved in oxaliplatin-induced EMT (Liu et al. 2019).
The involvement of the post-translational EMT regulators 
in drug resistance has been described (Fig. 1). It was demon-
strated that early stages of EMT involve a post-translational 
downregulation of E-cadherin, whereas loss of E-cadherin 
via transcriptional repression is a late event in EMT (Janda 
et al. 2006). As previously mentioned, the E3 ubiquitin-
ligase Hakai is a posttranslational regulator of E-cadherin 
stability (Fujita et al. 2002; Aparicio et al. 2012). Hakai is 
upregulated in gefitinib-resistant NSCLC cells that acquired 
EMT characteristics. Moreover, an increase of Hakai and a 
decrease in E-cadherin expression is also detected in gefi-
tinib-resistant clinical cancer samples and lung cell lines. 
This event was reversed by the dual action of histone dea-
cetylase (HDAC) and 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMGR) inhibitor, JMF3086. Indeed, JMF3086 
inhibited the Src/Hakai and Hakai/E-cadherin interaction 
reverting E-cadherin expression and reducing Vimentin and 
stemness to restore gefitinib sensitivity (Weng et al. 2019; 
Boumahdi and de Sauvage 2020). This study not only under-
scores the implication of the posttranslational regulators of 
the EMT in gefitinib-resistance (beyond EGFR mutations 
per se), but also draws the attention for therapeutic target-
ing of Hakai to block EMT and overcome chemoresistance 
in combination with chemotherapy. In fact, a recent study 
identified Hakin-1 as a novel specific small-molecule inhibi-
tor against Hakai, emerging as an effective therapeutic agent 
for EMT inhibition (Martinez-Iglesias et al. 2020). Given 
the mechanism of action of Hakai, it is expected that differ-
ent types of carcinomas, such as colorectal cancer or lung 
cancer, may benefit with this therapy (Figueroa et al. 2009; 
Aparicio et al. 2015; Castosa et al. 2018). Another important 
posttranslational mechanism that may impact therapy resist-
ance, is described in colorectal cancer (Díaz and de Herreros 
2016; Li et al. 2019). The transcription factor Zeb2 is a sub-
strate for the F-Box E3 ubiquitin-ligase FBXW7 in intesti-
nal stem cells upon GSK3β phosphorylation. In mouse and 
human colorectal cancer cell lines, the axis Zeb2/FBXW7 
induces EMT and metastasis, and it is linked to chemore-
sistance (Díaz and de Herreros 2016; Li et al. 2019). Other 
important proteins involved in ubiquitin–proteasome path-
way was recently reported to be involved in breast and pan-
creatic cancer cells (Lambies et al. 2019). It was shown that 
TGF-β-induced EMT activates the deubiquitinase USP27X, 
which stabilize Snail protein. In the absence of USP27X, 
Snail is degraded and the sensitivity to cisplatin is increased, 
opening new therapeutic strategies to overcome chemoresist-
ance (Lambies et al. 2019).
Regulation of the epithelial‑to‑mesenchymal 
transition by tumour microenvironment
Solid tumours are a cellular ecosystem termed tumour 
microenvironment (TME). In addition to tumour cells the 
cellular content of the TME is composed of resident and 
infiltrating non-tumour cells including endothelial cells, 
fibroblasts, various types of lymphatic cells such as T, B 
and NK cells; myeloid cells such as macrophages and granu-
locytes and others. A major component of the acellular frac-
tion of the TME is the extra cellular matrix (ECM), a net-
work of multiple categories of macromolecules. Other TME 
constituents are soluble products of the microenvironmental 
cells such enzymes, cytokines, chemokines and antibodies. 
The metabolome of the TME very often differs from the 
corresponding normal organ and hypoxia characterizes the 
TME of most solid tumours. Drugs may also be present in 
the TME of treated tumour bearers (Maman and Witz 2018). 
The TME is an arena for dynamic and constant interactions 
between tumour cells, their molecular products and host-
derived cells and molecules. The reciprocal tumour-host 
interactions lead to an evolving phenotype reprograming of 
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both interaction partners and may culminate in metastasis 
and therapy resistance (Dalton 1999; Morin 2003; Correia 
and Bissell 2012; Maman and Witz 2018).
The survival, propagation and the progression of cancer 
cells towards metastasis depend on intrinsic properties of 
the cancer cells as well as on cross-talk with their microen-
vironment (Klein-Goldberg et al. 2014; Maman and Witz 
2018). The spread of cancer cells from the primary site to 
secondary organ sites and then the establishment of new 
cancer lesions in these sites is a sequential multistep process. 
Each step of the metastatic cascade is jointly controlled by 
tumour-intrinsic factors as well as by those originating in the 
TME (Klein-Goldberg et al. 2014; Maman and Witz 2018). 
One of the initial phases of the metastatic cascade is driven 
by the activation of the EMT program that confers to tumour 
cells the capacity to invade neighboring tissues. Then, cells 
reach the circulation, spread throughout the body and subse-
quently metastasize to specific organs. EMT program is trig-
gered in response to TME-derived paracrine signals emit-
ted from resident or infiltrating non-tumour cells such as 
fibroblasts, macrophages or immunocytes (Lamouille et al. 
2014; Brabletz et al. 2018; Yang et al. 2020). The molecu-
lar program that drives EMT functions via miocroenviron-
mental multi-signaling pathways that cooperate and cross 
talk to each other. Among these are members of the TGF 
superfamily, VEGF, HGF, HIFs, Notch and Wnt, ECM 
components and microRNAs to mention but a few (Thiery 
et al. 2009; Lindsey and Langhans 2014; Mudduluru et al. 
2015; Ye and Weinberg 2015; Zhang et al. 2016; Dongre and 
Weinberg 2019). These, sometimes converging, signaling 
pathways upregulate several EMT-transcription factors such 
as Twist, Zeb1 and Snail (Cano et al. 2000; Peinado et al. 
2007; Taube et al. 2010).
These EMT-regulated factors act in concert to alter cel-
lular morphology, promote motility, reprogram ECM, and 
downregulate tight junctions (Peinado et al. 2007; Wheelock 
et al. 2008). Importantly, during EMT process distinct inter-
mediate stages are found, existing tumour subpopulations 
expressing phenotypes ranging from a complete epithelial 
to a complete mesenchymal one may co-inhabit single solid 
tumours. The microenvironmental host cells associated with 
different tumour subpopulations may also vary (Pastushenko 
et al. 2018). Moreover, it should also be remembered that 
the mesenchymal-tumour cells generated by the EMT pro-
cess exert various effects on microenvironmental cells that 
could impact tumour progression and drug resistance (Nas-
sar and Blanpain 2016; Dongre and Weinberg 2019). The 
main microenvironmental drivers of EMT will be discussed 
below (Fig. 2).
Fig. 2  Microenvironment drivers of the EMT as potential therapeutic 
target to overcome therapy resistance. Several microenvironment fac-
tors such as tumour associated macrophages (TAMs), cancer associ-
ated fibroblasts (CAFs), alterations in the extracellular matrix (ECM), 
hypoxic conditions, inflammatory and immune cells are EMT-drivers. 
These cells activate several signaling pathways such as TNF-α, TGF-
β, IL-1β, IL-6, VEGF, HGF, HIFs, NOTCH and WNT, inducing 
EMT-transcription factors
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Hypoxia
Hypoxia, characterizing the microenvironment of essentially 
all solid tumours, is a major driver of EMT. The hypoxia-
mediated effects are exerted by Hypoxia-Inducible Factors 
(HIFs), a family of transcriptional regulators that control 
functions involved in tumour progression such as extracel-
lular matrix (ECM) remodeling, cell survival and prolif-
eration, metabolism, inflammation and angiogenesis. HIFs 
also play pivotal functions in the EMT process and drug 
resistance (Rohwer and Cramer 2011; Balamurugan 2016; 
Schito and Rey 2017; Joseph et al. 2018). HIF-1, a member 
of the HIF family, upregulates the expression and activity 
of several EMT-inducing transcription factors including 
Twist, Zeb1 and Snail. Each of these factors alone has the 
capacity to induce EMT (Yang et al. 2008). These factors 
repress the expression by tumour cells of epithelial-specific 
proteins such as E-cadherin while inducing the acquisition 
of a mesenchymal phenotype in these cells. HIF-1 may exert 
its influence by functioning in concert with other factors. For 
example, HIF-1 engages in a crosstalk with members of the 
TGF-β family, being themselves strong inducers of EMT 
(the role of TGF-β family members in EMT is discussed 
separately). These 2 interaction partners cooperatively sup-
port EMT (Copple 2010).
The extracellular matrix
The extracellular matrix (ECM), a three-dimensional net-
work that surround the cells in a certain microenviron-
ment, is an important constituent of the TME that provides 
structural and biochemical support to such cells. Its main 
functions are to support cell adhesion and inter cellular 
communication (Hynes and Naba 2012). The ECM is com-
posed of macromolecules, such as integrins, collagen, gly-
coproteins, glycosaminoglycans and enzymes to name but a 
few. A review by Tzanakakis provides a detailed account of 
the ECM constituents that interact with EMT components 
thereby regulating this process (Tzanakakis et al. 2018). 
Deregulated ECM remodeling, induced by matricellular pro-
teins, reactive oxygen species, by hypoxia or by proteases, 
has a meaningful impact on tumour progression especially 
by being both affected by this process as well as influencing 
it. ECM remodeling involves alterations in the expression of 
proteoglycans, a reorganization of the collagen interactome, 
proteolysis of macromolecules and activation of integrins. 
These alterations in ECM structure and function drive EMT 
(Catalano et al. 2013; Nieberler et al. 2017; Paolillo and 
Schinelli 2019; Brassart-Pasco et al. 2020; Gerarduzzi et al. 
2020).
The inflammatory and immune microenvironment
Tumour promoting and tumour suppressive immunocytes 
and inflammatory cells as well as their molecular products 
are abundantly present in the TME (Maman and Witz 2018). 
The inflammatory cells as well as their secretome have the 
capacity to induce, drive and maintain EMT (Yan et al. 
2018; Fedele and Melisi 2020). Tumour-associated mac-
rophages (TAMs) are the largest non-tumour cell popula-
tion in the TME. These cells promote tumour progression 
by secreting the angiogenic cytokine VEGF, and by activat-
ing inflammatory pathways via pro-inflammatory cytokines 
(Noy and Pollard 2014; Ségaliny et al. 2015; Mantovani 
et al. 2017). TAMs also play a crucial role in the induction 
and maintenance of EMT (Song et al. 2017), for example by 
secreting pro-inflammatory cytokines such as TNF-α, TGF-
β, IL-1β, IL-6, CCL5 and CCL18. TAMs are involved in 
the activation of the EMT process by using various modes 
of action (Suarez-Carmona et al. 2017; Dominguez et al. 
2017). Other myeloid cells such as granulocytes or myeloid-
derived suppressor cells also induce EMT (Toh et al. 2011; 
Mayer et al. 2016; Sangaletti et al. 2016). Tumour infiltrating 
lymphocytes such as regulatory T cells (Kudo-Saito et al. 
2009) are also involved in the activation of EMT mainly via 
secretion of pro-inflammatory and other tumour-promoting 
cytokines. The cross talk between tumour and NK cells tak-
ing place in the microenvironment induces a skewed phe-
notype in NK cells becoming drivers rather than inhibitors 
of metastasis. This metastasis-promoting function is imple-
mented via the activation of EMT. The tumour infiltrating 
NK cells secrete pro-inflammatory cytokines such as IL-6 
and activate various matrix metalloproteinases that facilitate 
tumour invasion (Cantoni et al., 2016; Lee et al. 2017b). 
EMT may induce immune suppressive properties in cancer 
cells (Ricciardi et al. 2015; Terry et al. 2017) or modify their 
immunogenicity resulting either in escape from anti-tumour 
immune responses or in the generation of new tumour-asso-
ciated epitopes (Chockley and Keshamouni 2016; Poggi and 
Giuliani 2016).
Cancer‑associated fibroblasts
Cancer-Associated Fibroblasts (CAFs) together with mye-
loid-derived cells (mostly macrophages) and to lesser degree 
endothelial cells are the most abundant non-tumour cells 
in the TME. CAFs are generated as a response to activa-
tion signals delivered to fibroblasts from tumour and non-
tumour cells in the TME. Such signals which mediate their 
function by contact between tumour cells and fibroblast or 
by soluble factors such as IL-1 or IL-6, induce the CAF 
phenotype characterized by the expression of α-smooth 
muscle actin (α-SMA) (Sahai et al. 2020). CAFs promote 
cancer progression by EMT facilitating functions such as 
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reprograming of ECM and of the phenotype of tumour and 
of other TME-residing cells. These functions are mediated 
by cellular contacts between CAFs and tumour cells or other 
stromal cells or by soluble factors (Choe et al. 2013; Yu et al. 
2014; Chen and Song 2019). Among the EMT-enhancing 
factors released from CAFs are TGF-β and proinflammatory 
cytokines (Yu et al. 2014; Fang et al. 2018).
MicroRNAs
MicroRNAs (miRNAs) are small non-coding RNAs that 
extensively regulate gene expression by binding mRNA 
thereby inhibiting its translation. This capacity enables 
miRNAs to function as potent regulators of normal cel-
lular physiology and when aberrantly expressed, also of 
pathological processes such as cancer progression (Fabian 
et al. 2010; Markopoulos et al. 2017). EMT is regulated by 
miRNAs. These molecules downregulate EMT-associated 
transcription factors, or alternatively act as their functional 
mediators in the regulation of the EMT process (Abba et al. 
2016). As noted above TGF-β, Notch, and Wnt signaling 
pathways are intimately linked to the EMT process. The dis-
covery of a signature of 30 miRNAs, each regulating all of 
these 3 pathways and of the target genes of these miRNAs, 
demonstrated the occurrence of an EMT-promoting cross 
talk between these pathways (Zoni et al. 2015). Multiple 
miRNAs including miR-200, miR-34, miR-338-3p and oth-
ers are involved in the regulation of EMT (Park et al. 2008; 
Li et al. 2016; Nie et al. 2019). Members of the miR-200 
family may serve as prototypes for miRNAs that influence 
EMT. These miRNAs have been extensively studied for their 
role as master regulators (suppressors) of EMT.
TGF‑β
TGF-β is a multifunctional cytokine produced by tumour 
as well as by host-derived cells within the TME (Izraely 
et al. 2017; Ahmadi et al. 2019). TGF-β regulates various 
functions of tumour cells and of host-derived cells within 
the TME by employing TGF-β type I and type II receptors 
(Heldin and Moustakas 2016). TGF-β can be regarded as a 
prototype of molecules that exert yin-yang functions with 
respect to tumourigenesis and tumour progression (Witz 
2008). In early phases of tumour progression TGF-β usu-
ally functions as a tumour suppressor whereas in later phases 
it promotes malignancy (Yang et al. 2010; Suriyamurthy 
et al. 2019) mainly by acting as the main inducer and driver 
of EMT, leading to tumour progression towards metastasis 
(Hao et al. 2019). Complexes of TGF-β and its kinase recep-
tors activate the intracellular transcriptional effectors Smad. 
These, in turn, regulate the expression of EMT-mediating 
genes Twist, Zeb1 and Snail. Following are some selected 
studies documenting the role of Smad in TGF-β-mediated 
EMT (Vincent et al. 2009; Kim et al. 2016; Yu et al. 2016; 
Yeh et al. 2018; Tong et al. 2020). TGF-β can also induce 
EMT by altering the mechanical architecture (cytoskeletal 
remodeling) of cancer cells to a motile phenotype (Gladilin 
et al. 2019). This Smad-independent process involves the 
activation of ERK (Lee et al. 2007). Similarly to the TGF-β/
HIF-1 cooperation (Copple 2010) TGF-β collaborates with 
other EMT inducers such as Wnt or Notch to co-stimulate 
EMT thereby promoting an invasive and pro-metastatic phe-
notype of tumour cells (Murillo-Garzón et al. 2018).
Microenvironmental regulation of EMT: 
influence on drug resistance
Tumour microenvironment, as an important regulator of the 
EMT, has an impact on therapy resistance. Many publica-
tions have highlighted that signals such as growth factors 
or cytokines originated from tumour stroma may regulate 
EMT-related drug resistance (Shibue and Weinberg 2017). 
Between them, one of the extracellular matrix factors 
secreted by CAFs are TGF-β1 and hyaluronan. The first evi-
dence showing the properties of hyaluronan in cancer resist-
ance was reported in a model of naked rat mole fibroblasts 
secreting high molecular mass hyaluronan, that hyper sen-
sitize cells to contact inhibition and cell cycle arrest (Tian 
et al. 2013, 2015). Those CAFs maintaining high autocrine 
production of hyaluronan are more motile, whereas CAFs 
with fewer motile characteristics synthesized higher TGF-
β1. TGF-β1 did not stimulate motility but enhance inva-
sion and EMT markers, indicating different mechanisms to 
drive carcinoma progression (Costea et al. 2013). Moreo-
ver, colorectal cancer subtypes with poor prognosis share 
a gene program driven by TGF-β secreted by tumour stro-
mal cells, suggesting its association to treatment resistance 
(Calon et al. 2015). On the other hand, it has been reported 
that IL-6 from CAFs enhanced TGF-β-induced EMT in 
non-small lung cancer cells (NSCLS). Treatment with cis-
platin increased TGF-β expression, and the conditioned 
media from cancer cells activated fibroblasts and increased 
their IL-6 production, concluding that IL-6 contribute to 
induce a paracrine loop that intercommunicated CAFs and 
NSCLS, resulting in chemoresistance (Abulaiti et al. 2013; 
Shintani et al. 2016). Moreover, oncostatin M (OSM), an 
IL6 cytokine family member, induced the expression of 
Zeb1, Snail (SNAI1), and OSM receptor (OSMR), inducing 
the regulation of EMT program and conferring resistance 
to gemcitabine, a current first-line therapy for pancreatic 
ductal adenocarcinoma (Smigiel et al. 2017). Moreover, 
as previously mentioned hypoxia is a hallmark of solid 
tumours’ microenvironment and is associated to therapeu-
tic resistance. The hypoxia-induced gene, procollagen-lysine 
2-oxoglutarate 5-dioxygenase 2 (PLOD2), was induced by 
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hypoxia conditions in biliary tract cancer cell and influence 
gemcitabine resistance through EMT (Okumura et al. 2018). 
HIF-1 has also been associated to therapy resistance. Indeed, 
gemcitabine resistance is associated with EMT and induc-
tion of HIF-1α in pancreatic cancer cells (Wang et al. 2014), 
leading to the pharmacologic manipulation of HIF-1α as 
novel therapeutic approach to overcome resistance. It is also 
important to mention that exosomes are also responsible of 
therapy resistance as they contain molecules that influence 
tumour progression. Indeed, tumour-derived exosomes may 
favor therapy resistance in the tumour microenvironment and 
induces EMT (Steinbichler et al. 2019). Indeed, exosomal 
miR-155 is linked to the development of drug resistance in 
several types of cancers via EMT, such as cisplatin resist-
ance in oral cancer cells and in paclitaxel-resistance in gas-
tric cancer cells (Wang et al. 2019a; Steinbichler et al. 2019; 
Kirave et al. 2020).
The interactions between cancer cells and immune micro-
environment also play a crucial role on EMT and therapy 
resistance. Cancer cells produce chemokines and cytokines 
which recruit immune cells such as T and B lympho-
cytes, macrophages, neutrophils, between others (Maman 
and Witz 2018). For instance, in lung cancer, it has been 
recently reported that epigenetic suppression by Snail of 
the ubiquitin specific protease 4 (USP4) expression is an 
underlying mechanism to contribute to inflammation and 
therapeutic resistance by tumour-associated macrophages 
(Lai et al. 2020). Importantly, immunotherapy has emerged 
as a promising therapeutic strategy to treat cancer. Particu-
larly, the use of immune-inhibitors targeting the interaction 
between PD-1 and PDL-1 or CTLA-4 have proved important 
benefit in cancer patients (Sharma et al. 2017; Havel et al. 
2019). Although future investigations are required to deeply 
understand the molecular mechanism of the immune scape 
mechanisms, important contribution of EMT to immune 
escape has started to come out as well as it has been eluci-
dated the potential use of EMT markers for immune therapy 
selection. The co-expression of the N-cadherin and Vimentin 
EMT markers together with PDL-1 was detected in CTCs of 
recurrent patients treated with nivulumab, a PD-L1 inhibi-
tor. This evidence suggests that EMT and PDL-1 may serve 
to identify patients that do not respond to immunotherapy 
(Raimondi et  al. 2017). Moreover, immunosuppression 
of CD8 + tumour-infiltrating lymphocytes (TIL) is linked 
to EMT. In this sense, microRNA-200 (miR-200) targets 
PD-L1. The TF Zeb1 activates EMT and transcription-
ally repressed miR-200, which in consequence attenuated 
miR-200 repression of PD-L1 on tumour cells, leading to 
CD8 + T-cell immunosuppression. This important work sug-
gests that patients on whom tumour progression is driven 
by EMT activators may respond to PD-L1 inhibitors (Chen 
et al. 2014). Moreover, EMT transcriptional scoring is a 
very promising strategy to determine treatment response and 
survival. Indeed, the EMT-transcriptional score in different 
tumour subtypes result in a better response to immunother-
apy of those patients presenting luminal phenotype (more 
epithelial phenotype), than those presenting basal phenotype 
(mesenchymal phenotype). Importantly, different response 
to therapeutic administration with or without paclitaxel was 
observed while comparing epithelial- and mesenchymal-like 
phenotype in ovarian cancers, showing that mesenchymal-
like tumours do not always show resistance to chemotherapy 
(Choi et al. 2014; Tan et al. 2014). Additionally, high score 
of EMT markers is related to immune expression markers, 
such as PDL-1 in lung adenocarcinomas or head and neck 
squamous cell carcinoma (Mak et al. 2016; Ock et al. 2016; 
Lou et al. 2016). Future investigations are required to under-
stand the molecular mechanism by which the microenviron-
ment may influence EMT and therapy resistance. In this con-
text, multidisciplinary approaches including bioinformatics 
and pharmacology are important strategies to investigate the 
impact of EMT-induced therapeutic resistance.
Bioinformatic investigation in drug 
resistance and in EMT
Bioinformatic and pharmacogenomics for drug 
and target optimization and for drug resistance 
detection
In the future, bioinformatic approaches will importantly 
benefit the understanding of clinical relevant phenotypic 
programs to develop better-targeted therapies. It is becom-
ing increasingly apparent that the use of bioinformatics and 
patient samples will help to study the biological impact of 
EMT depending on the transition dynamics, as well as to 
elucidate the role of EMT in drug resistance (Celià-Terrassa 
et al. 2018). Important publications have used mathemati-
cal or computational methods to study EMT and its poten-
tial implication in drug resistance. For instance, the use of 
RACIPE mathematical modeling has shown a significant 
negative correlation between Twist1 and E-cadherin, and a 
positive correlation between Twist1 and Vimentin. Moreo-
ver, Twist1 overexpression enhances genome instability in 
the context of EMT, thus contributing to cellular hetero-
geneity and potentially influencing chemoresistance (Khot 
et al. 2020). On the other hand, a computational approach 
named MAGIC (Markov affinity-based graph imputation of 
cells) was developed for recovering missing gene expres-
sion in single-cell data. MAGIC reveals that the majority of 
cells that reside in an intermediate E/M state display stem-
like characteristics (van Dijk et al. 2018). Importantly, drug 
resistance in carcinoma cells seems to be maximal at an 
intermediate level of EMT-program activation (Shibue and 
Weinberg 2017). Foroutan et al. performed a comprehensive 
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bioinformatics approach to show that TGFβ-driven EMT 
presents a low mutational burden across the TGFβ signal-
ing pathway. Moreover, a significant variation was detected 
in the response of high scoring cell lines to some common 
cancer drugs. This scoring was applied to pan-cancer data 
from The Cancer Genome Atlas, showing that tumour types 
with high scores had significantly lower survival rates than 
those with low scores and carried a lower mutational burden 
in the TGFβ pathway. The pan-drug analysis also showed 
that there was no general drug resistance associated with 
TGFβ-induced EMT, thus reinforcing the idea of a drug-
specific effect (Foroutan et al. 2017).
Pharmacogenomics is a rapidly growing field framed 
within genome-wide studies that aims to elucidate how 
human gene products (i.e. proteins) affect the response to 
drugs and pharmacological treatments (Roden et al. 2019). 
This relatively new field combines pharmacology and 
genomics to develop effective, safe medications and doses 
that can be tailored for specific tumour subtypes and spe-
cific patient risk factors (Harper and Topol 2012). It is well 
known that drugs can have multiple molecular targets inside 
our body and that the specific molecular interaction of many 
drugs is often unknown and can be quite variable from one 
individual to another. Genome and proteome-wide informa-
tion associated to the drugs activity in human cells is essen-
tial to generate better maps of the molecular targets of each 
drug (De Las Rivas et al. 2018). Construction of this type of 
drug-target interaction mapping has been successful in the 
field of cancer genomics thanks to the possibility of testing 
the activity of hundreds of cancer drugs in multiple human 
cancer cell lines (Arroyo et al. 2020). Similar studies using 
genomic data combined with drugs activity are needed to 
elucidate at molecular level the genetic and somatic basis 
for inter-individual differences in drug response. The dis-
covery of specific genetic factors that modulate the reactiv-
ity or resistance of a patient with cancer to a drug is one 
of the main objectives of pharmacogenomics, knowing that 
these factors can be critical to understand the safety, toxicity 
and efficacy of drugs in individual patients or in groups of 
patients (Lee et al. 2005; Chenoweth et al. 2020). An exam-
ple of this is the discovery of multiple genetic polymorphism 
in gene CYP2D6, that encodes a cytochrome P450, and it 
is responsible for the metabolism of 25% of all drugs cur-
rently on the market. This gene presents polymorphism that 
significantly affect drug action. In fact, in breast cancer it has 
been shown that the allelic variations in CYP2D6 is a very 
important determinant of tamoxifen’s activity and toxicity 
(Huang and Ratain 2009). Another example of how pharma-
cogenomics can reveal resistance mechanisms is the detec-
tion, in tumours treated with EGRF inhibitors (erlotinib, 
gefetinib, afatinib), of the upregulation or amplification of 
other genes such as MET and HER2 that cause treatment 
failure because they replace the EGRF function (Gillis and 
McLeod 2016).
A key challenge that can be also addressed using pharma-
cogenomics is the frequent problem of ineffective response 
to drugs (Relling and Evans 2015; Wang and Weinshilboum 
2019). The complexity drug interactions (due to the exist-
ence of multiple drug-targets, drug-drug cross reactions, 
target-to-target interferences, etc.) and the effect of mul-
tiple environmental factors can significantly contribute to 
drug inefficiency, which often also is associated to specific 
individual variability. In this regard, genetic factors (such 
as inherited variability of drug targets, drug metabolizing 
enzymes, and/or drug transporters) also appear to have a 
major impact on drug resistance (Roden et al. 2019; Che-
noweth et al. 2020). In fact, specific individual resistance 
may be associated, for example, with the multi-drug resist-
ance proteins (MRPs). These proteins present genetic poly-
morphisms that cause large differences in their expression 
and activity level from some individuals to others, and they 
are key factors in the development of resistance to differ-
ent classes of anticancer drugs (Yu et al. 2007; Zhang et al. 
2015).
Cancer drug resistance: inherited or acquired
Focusing on cancer therapy, the success of target-driven 
anticancer drugs is usually limited by the development of 
several types of resistance (Rueff and Rodrigues 2016): (i) 
inherited resistance (sometimes defined as primary resist-
ance) and (ii) acquired resistance (defined as secondary 
resistance). In both cases, resistance emerges in the context 
of cancer heterogeneity, either heterogeneity reflected by 
inter-individual differences within the same type of tumours, 
or heterogeneity reflected by intra-tumoural differences that 
reveal the phenotypic diversity of cancer cells co-inhabiting 
a single tumour mass (Shibue and Weinberg 2017). The first 
type of cancer heterogeneity (inter-individual) is often cor-
related with inherited primary drug resistance. The second 
type of cancer heterogeneity (intra-tumour) usually cor-
responds to secondary drug resistance, which is acquired 
throughout the process of tumour evolution. In both cases, 
pharmacogenomic studies help elucidate the molecular 
origin of resistance to specific anticancer drugs. For exam-
ple, resistance to small-molecule tyrosine kinase inhibitors 
(TKIs, such as imatinib, erlotinib, gefitinib, and sorafenib), 
is usually acquired and shows a very different evolution in 
different individuals. Also genome-wide studies have shown 
that resistant individuals, compared to non-resistant, com-
monly harbor acquired somatic point mutations detected 
in genes NTRK1, KDR, TGFBR2 and PTPN11 and copy 
number alterations in CDK4, CDKN2B and ERBB2 (Gillis 
et al. 2017).
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EMT‑induced drug resistance
EMT-induced drug resistance can be associated in most 
cases with the second type of cancer heterogeneity, intra-
tumour, described above. Moreover, the phenotypic diversity 
of neoplastic cells within a tumour is considered a major 
driver of the development of resistance to therapy. In this 
context, one of the critical cell subpopulations playing a 
major role in the generation of drug resistance corresponds 
to the tumour cells that undergo EMT. Large-scale pharma-
cogenomics have been used to unravel how EMT can drive 
resistance to chemotherapeutic drugs (Hong et al. 2018). 
In this respect, overexpression of several genes (like inte-
grin beta-3, ITGB3 also called CD61; and integrin beta-4, 
ITGB4), which promote EMT, have been directly related 
with chemoresistance (Li et al. 2017; Hong et al. 2018). This 
resistance has been linked to the activation of EMT tran-
scription factors Snail (SNAI1) and Slug (SNAI2) in several 
types of cancer (Haslehurst et al. 2012). Overexpression of 
other EMT-inducing genes, such as Zeb1 have also been 
shown to closely correlate with resistance to gemcitabine, 
5-fluorouracil, and cisplatin (Arumugam et al. 2009).
The specific mechanisms of how EMT induces drug 
resistance are still under study and may vary in different 
types of cancer. For example, some results observed in lung 
cancer (Chae et al. 2018), indicate that EMT causes a change 
in tumours that move them from a hot to a cold state, increas-
ing the resistance of tumours to immunotherapy. In fact, it 
has been shown in non-small cell lung cancer (NSCLC) that 
an EMT signature is inversely associated with T-cell infiltra-
tion (Chae et al. 2018). It has also been shown that revers-
ing EMT causes an increase in anticancer drug sensitivity 
(Huang and Huang 2016). Another relevant discovery in this 
context is that EMT often generates cells with properties of 
stem cells (Mani et al. 2009), which are more resistant to 
apoptosis and other types of programmed death, improving 
the capacity for self-renewal. Finally, as explained above 
therapeutic resistance is in many cases linked to an hybrid 
epithelial-to-mesenchymal phenotype (Williams et al. 2019).
Pharmacological approaches for therapies 
of EMT induced drug resistance
Due to the fact that EMT is implicated in cancer metastasis 
and induction of drug resistance, targeting EMT may have 
a therapeutic value (Malek et al. 2017). As previously men-
tioned, interesting findings have been obtained about the 
correlation between either epithelial or mesenchymal status 
of the cell with drug resistance (Miow et al. 2014; Biddle 
et al. 2016). There are on-going investigations about the pos-
sibility that the specific state of these two phenomena could 
be reversible, among them also ours (Brozovic, unpublished 
data) what brought us to the thinking that possible strategy 
to overcome or slow down the disease progression could be 
targeting those specific states by targeting their regulators. 
There are several great review papers which are discussing 
in details therapeutic targets, small-molecule inhibitors of 
tumour plasticity as well as natural compounds which could 
be used for targeting tumour metastasis (Kotiyal and Bhat-
tacharya 2014; Varghese et al. 2018; Yang et al. 2019; Feng 
et al. 2020). Furthermore, very nicely presented literature 
overview was given in a context of compounds and drugs, 
which target microenvironmental-induced EMT (Gao and 
Mittal 2012; Maman and Witz 2018). It is also known that 
many of EMT drivers are epigenetically regulated, by DNA 
methylation, histone modifications and etc., pointing out the 
epigenetic regulators could also be interesting therapeutic 
targets for overcoming EMT (Mishra and Johnsen 2014). 
As mentioned above, EMT is regulated by various mediators 
such as transcription factors, microenvironmental factors, 
signaling pathways, RNA‐binding proteins and miRNAs. In 
a line with this, there are several possible targets to over-
come EMT induced drug resistance. The detailed discus-
sion on all the targets is not possible within the limits of 
this review but the one investigated lately in the context of 
EMT induced drug resistance particularly are displayed in 
Table 1. Briefly, transcription factors such as Snail, Twist, 
Zeb or Stat3 are activated early in EMT process (Lamouille 
et al. 2014). Due to their importance in regulation of EMT, 
the inhibition of their expression or activation may be one 
of the ways to block EMT. Many signaling pathways, such 
as TGF‐β1, NF‐κB, Wnt, Akt, peroxisome proliferator 
activated receptor (PPAR), and Notch pathways, and the 
renin‐angiotensin system (RAS) contribute to the EMT. 
Different compounds are described as possible inhibitors of 
these signaling pathways for overcoming EMT (Feng et al. 
2020). Recently, many miRNAs have been found to promote 
or suppress EMT in tumours and sensitize tumour cells to 
chemotherapeutics (Zhang and Ma 2012; Brozovic et al. 
2015; Brozovic 2017). Moreover, post-translational EMT-
regulators, such as Hakai, FBXW7 or USP27X have been 
emerged as new therapeutic strategies to overcome therapy 
resistance (Aparicio et al. 2012, 2015; Díaz and de Herre-
ros 2016; Castosa et al. 2018; Lambies et al. 2019; Li et al. 
2019; Martinez-Iglesias et al. 2020).
Some novel mediators specifically involved in EMT-
induced drug resistance are also shown in Table 1. Inhibitor 
of apoptosis-stimulating protein of p53 (iASPP), which was 
previously confirmed as EMT inducer, promotes miR-20a 
expression in a p53-dependent manner. MiR-20 upregula-
tion induces EMT and cisplatin resistance via F-box and 
leucine rich repeat protein 5/BTG anti-proliferation factor 3 
(FBXL5/BTG3) signaling in cervical cancer HeLa and SiHa 
cell lines (Dong et al. 2016; Xiong et al. 2017). Forkhead 
box protein C2 (FOXC2) was shown to promote resistance 
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Table 1  Potential new targets to overcome EMT-induced drug resistance
AKR1C1, aldo–keto reductase family 1 member C1; ANXA2, annexin A2; CBF1, centromere-binding protein 1; CDH1, E-cadherin; COX-2, 
cyclooxygenase-2; CXCR7, C-X-C chemokine receptor type 7; FAK, focal adhesion kinase; FBXW7, F-Box E3 ubiquitin-ligase; Hakai, HYB 
domain E3 ubiquitin, ligase; HectD1, E3 ubiquitin-ligase; HGF, hepatocyte growth factor. IGF-1, insulin like growth factor 1; MCL-1, myeloid 
leukemia cell differentiation protein; Oct4, octamer-binding transcription factor 4; OSM/OSMR, oncostatin-M/oncostatin M receptor; PARP3, 
poly(ADP-Ribose) polymerase family member 3; PHD3, prolyl-4-hydroxylase domain 3; PLOD2, procollagen-lysine,2-oxoglutarate 5-diox-
ygenase 2; PRKCA, protein kinase C alpha; PTEN, phosphatase and tensin homolog; Ras, rous sarcoma virus; SHKBP1, SH3KBP1 binding 
protein 1; SMAD, mothers against decapentaplegic homolog 1; SOX2, sex determining region Y-box 2 (or SRY); SphK1, sphingosine kinase 
1; ST3GAL1, ST3 beta-galactoside alpha-2; USP27X, X-linked ubiquitin carboxyl-terminal hydrolase 27, deubiquitinase; WDR5, WD repeat 
domain
EMT inducer Proposed targets Developed resistance Tumour/tumour cell type Reference
Snail (SNAI1)⇑ Snail Cisplatin Head and neck Ota et al. (2016)
Twist (TWIST1) ⇑ Twist Erlotinib
Osimertinib
Non-small cell lung Yochum et al. (2019)
Hakai (CBLL1) Hakai Gefitinib /cisplatin Lung Liu et al. (2018); Weng et al. 
(2019); Martinez-Iglesias 
et al. (2020)
FBXW7 FBXW7 Cisplatin Colorectal Li et al. (2019)
CAFs ANXA2,
HGF/IGF-1/ANXA2
EGFRi Non-small cell lung Yi et al. (2018)
CAFs IL-6 Paclitaxel Ovary Wang et al. (2018)
IL-1β⇑ AKR1C1 Cisplatin Bladder Matsumoto et al. (2016)
IGF-1⇑ SPHK1 Paclitaxel Lung Wu et al. (2019b)
OSM&IL-6 (tumour 
microenvironment)⇑
OSM/OSMR Gemcitabine Pancreas Smigiel et al. (2017)
 + TIPACF7⇑ HECTD1 Cisplatin Breast Duhamel et al. (2018)
TGF-β1 miR-134/-487b/-655 cluster
MAGI2
Gefitinib Lung adenocarcinoma Kitamura et al. (2014)
TGF-β1 MCL-1 Cisplatin Non-small cell lung Toge et al. (2015)
TGF-β1 CXCR7 Cisplatin
Etoposide
Lung Wu et al. (2016)
TGF-β1 TGF-β1 Oxaliplatin Colorectal Mao et al. (2017)
TGF-β PHD3 (- EMT regulator) Erlotinib Lung Dopeso et al. (2018)
TGF-β1 ST3GAL1 Paclitaxel Ovary Wu et al. (2018)
TGF-β USP27X, Snail Cisplatin Breast and pancreas Lambies et al. (2019)
TGF-β1 WDR5 Paclitaxel Breast Punzi et al. (2019)
Hypoxia HIF-1 (HIF1A) Cisplatin
Cetuximab
Dasatinib
Head and neck squamous Wiechec et al. (2017)
Hypoxia PLOD2 Gemcitabine Biliary tract Okumura et al. (2018)
Tumour-derived exosomes miR-155 Cisplatin Oral cancer Kirave et al. (2020)
iASPP⇑ miR-20, FBXL5/BTG3 Cisplatin Cervical Xiong et al. (2017)
CD73⇑ CD73 Trastuzumab Lung Turcotte et al. (2017)
FOXC2⇑ FOXC2, AKT/GSK3β Cisplatin Non-small cell lung He et al. (2018)
KPNA3⇑ KPNA3, AKT/ERK Sorafenib Hepatocellular Hu et al. (2019)
PRRX1⇑ SIRT1-PRRX1-KLF4-ALDH1 Paclitaxel Breast Shi et al. (2018)
Sema4C⇑ Sema4C, miR-31-3p Cisplatin Cervical Jing et al. (2019)




Colon Chien et al. (2016)
miR-93⇑ PTEN Doxorubicin Breast Chu et al. (2017)
miR-296-3p⇑ PRKCA-FAK-RAS-cMYC Cisplatin Lung adenocarcinoma Fu et al. (2017)
miR-216a/-217⇑ PTEN, SMAD Sorafenib Liver Xia et al. (2013)
miR-574-3p⇓ Zeb1 Cisplatin Gastric Wang et al. (2019b)
miR-509 and miR-1243⇓ CDH1 Gemcitabine Pancreas Hiramoto et al. (2017)
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to the same drug by induction of EMT in non-small cell lung 
cancer A549 cells by activating v-akt murine thymoma viral 
oncogene homolog 1/ Glycogen synthase kinase 3 (AKT/
GSK3) signaling pathway and increased expression of Snail 
(He et al. 2018). Cisplatin resistance was also induced by 
Sema4C, and upregulation of miR-31-3p which reversed 
EMT-mediated biological functions in human cervical can-
cer HeLa, Caski, Siha and C33a cell lines (Jing et al. 2019). 
It was proposed that depleting sirtuin 1 (SIRT1) accelerates 
the degradation of paired related homeobox 1 (PRRX1) and 
disinhibits kruppel-like factor 4 (KLF4) transcription, lead-
ing to a partial MET, occurrence of aldehyde dehydrogenase 
1 (ALDH1)-positive cancer stem cells, distant metastases 
and resistance to paclitaxel. Reduced nuclear level of SIRT1-
PRRX1 axis is positively correlated with lung metastasis 
of breast cancer (Shi et al. 2018). Tyrosine-protein kinase 
receptor TYRO3 is overexpressed in the early stage of colon 
cancer development and aberrant expression of TYRO3 pro-
motes tumourigenesis and induces EMT through the reg-
ulation of SNAI1. Blocking TYRO3 signaling by human 
anti-TYRO3 antibody ameliorates cancer malignancy and 
increased sensitivity to paclitaxel, oxaliplatin and 5-fluoro-
uracil in different colon cancer cell lines (Chien et al. 2016). 
Expression of ectonucleotidase CD73 by tumour, stromal 
and immune cells is associated with immune suppression 
(Allard et al. 2017). But it was shown that expression of 
CD73 is associated with extracellular matrix organization, 
TGF-β genes, EMT, hypoxia-inducible factor-1 (HIF-1) as 
well and is mediating resistance to trastuzumab in human 
breast cancer (Turcotte et al. 2017). A novel KPNA3-AKT-
ERK-TWIST signaling cascade that promotes EMT and 
mediates sorafenib resistance was described in human hepa-
tocellular cell lines Huh7 and HepG2 cells (Hu et al. 2019). 
Moreover, sorafenib resistance was induced by SNHG3 
overexpression in several human hepatocellular cells PLC/
PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC‐7721, 
and HCCLM3 EMT via miR-128/CD151 cascade activation 
(Zhang et al. 2019).
Conclusions
The heterogeneity and plasticity of EMT phenotype are fea-
tures not only involved in metastasis, but also in drug resist-
ance. In recent years, new molecular insights have come out 
with the implication of EMT in drug resistance thanks to the 
in vitro and in vivo studies in preclinical tumour models and 
clinical settings. The knowledge of intermediate E/M states, 
that represent more properly the reality within the tumour, 
together with the influence of tumour microenvironment and 
cellular stemness, has opened new understanding regarding 
to the impact of the EMT to therapy resistance. Moreover, 
new therapeutic strategies based on epithelial plasticity have 
been proposed to overcome therapy resistance. The devel-
opment of plasticity inhibitors may have a great potential 
in cancer treatment as this type of drugs may prevent both 
drug resistance and cancer metastasis. Compounds targeting 
regulators of this plasticity could also work well with chem-
otherapy or targeted therapy drugs improving in that way the 
clinical outcomes of cancer patients. The integration of bio-
informatics, pharmacogenomics and chemical genomic data 
will be crucial to identify both therapeutic targets and novel 
chemosensitizing drugs to overcome resistance to multiple 
chemotherapies. A wide range of targets associated with 
EMT is expected to be elucidated in the future, thus allow-
ing to overcome therapy resistance. This will allow paving 
an alternative path for drug discovery even for proteins that 
cannot be pharmacological targeted nowadays.
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